or Call Now 800-952-7687
ProstRcision®
We don’t want to manage your cancer. We want to cure it.
Since 1979, Radiotherapy Clinics of Georgia (RCOG) has specialized in curing prostate cancer, not just treatment of the disease. We’ve treated more than 11,000 men with ProstRcision and have tracked each one of them before and during treatment as well as for years afterwards. As a result, we’ve compiled one of the largest computerized databases on prostate cancer in the United States. This information helps us tremendously as we treat our current patients. It also allows us to track our overall cure rate and provide patients with their Individual Cure Rates (ICR).
Learn more about achieving the best chance for cure and get your Individual Cure Rate at ProstRcision.com.
The Process.
The actual procedure we use is called ProstRcision®, a process by which tiny seed implants containing radiation destroy the prostate from within and kill the cancer. The seed implants give our doctors pinpoint accuracy to then go after the cancer with external beam treatment, and the database gives us a wealth of information based on past results. This combination of technique and data is why ProstRcision has the world’s highest proven cure rate for prostate cancer.
Tough Standards.
By our standards, for a man to be considered cured, he must have a PSA level of 0.2 or less, 10 years after he was treated. That’s a high bar to clear and we’re proud to say that 83 percent of our patients do. We base our cure rate on a 10-year period. Only Johns Hopkins Hospital uses a similar measurement.
Less surgery, fewer risks.
We can’t guarantee you won’t have side effects. But compared to a procedure like a radical prostatectomy, ProstRcision involves far less surgery. This greatly increases the chance you’ll maintain important muscle control and sexual function. And patients who have ProstRcision can return to work the day after the first part of the procedure.
We have a separate website dedicated to ProstRcision that includes a thorough Q&A section to help you understand prostate cancer and how you can have a major role in deciding your treatment method. You can also read survivor stories and join our online Forum. The Forum features discussions about prostate cancer and ProstRcision. Members include our current and former patients and men like yourself, who are still deciding on a course of treatment. To view this site, click here.
1.Critz FA, and Levinson K.: 10-Year Disease-Free Survival Rates After Simultaneous Irradiation For Prostate Cancer With A Focus On Calculation Methodology. J Urol 172: 2232-2238, 2004. 2.Han M, Partin AW, Piantadosi S, Epstein JI, and Walsh PC.: Era Specific Biochemical Recurrence-Free Survival Following Radical Prostatectomy For Clinically Localized Prostate Cancer. J Urol 166: 416-419, 2001. Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC and Catalona WJ.: Intermediate Term Biochemical progression Rates After Radical Prostatectomy and Radiotherapy In Patients With Screen Detected Prostate Cancer. J Urol 174: 126-130, 2005. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, and Kattan MW. Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. J Clin. Onc. Vol. 23, (28): 7005-7012, 2005 Touijer K, Cronin AM, Vickers AJ, Secin FP, Bianco FJ, Guillonneau BD. Oncological Outcome After Laparoscopic Radical Prostatectomy: 10 Years Experience. J Urol 179, (4): 558, 2008 Badami KK, Kaul S, and Menon M.: Evolution Of Robotic Radical Prostatectomy. Assessment After 2766 Procedures. Cancer 110 (9): 1951 – 1958, 2007. 3.Kuban D, Thames H, Levy L, Horwitx E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, and Zietman A.: Failure Definition – Dependent Differences In Outcome Following Radiation For Localized Prostate Cancer: Can One Size Fit All? Int J Rad Onc Biol Phys 61 (2): 409-414, 2005. 4.Kuban DA, Levy LB, Potter L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, and Horwitz EM.: Comparison Of Biochemical Failure Definitions For Permanent Prostate Brachytherapy. Int J Rad Onc Biol Phys. 65 (5): 1487-1493, 2006. 5.Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS, and Kirb LJ.: Ten-Year Disease Free Survival After Transperineal Sonography-Guided Iodine-125 Brachytherapy With Or Without 45-Gray External Beam Irradiation In The Treatment of Patients With Clinically Localized, Low to High Gleason Grade Prostate Carcinoma. Cancer 83 (5): 989-1001, 1998. 6.Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, isters LL, and Katz AE.: Whole Gland Primary Prostate Cryoablation: Initial Results From the Bryo On-Line Data Registry. J Urol 180:554-558, 2008. 7.Demanes DJ, Rodrigues RR, Schour L, Brandt D, and Altieri G.: High-Dose –Rate Intensity-Modulated Brachytherapy With External Beam Radiotherapy For Prostate Cancer: California Endocurietherapy’s 10-Year Results. Int J Rad Onc Biol Phys, 61 (5): 1306-1316, 2005. 8.Slater JD, Rossi CJ, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, and Slater JM.: Proton Therapy For Prostate Cancer: The Initial Loma Linda University Experience. Int J. Rad Onc Biol Phys. 59 (2): 348-352, 2004. 9.Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, and Sangvhi NT.: Phase I/II Trial of High Intensity Focused Ultrasound for the Treatment of Previously Untreated Localized Prostate Cancer. J Urol 178: 2366-2371, 2007. 10.Bentzen SM, Wasserman TH. Editorial: Balancing on a Knife’s Edge: Evidence-Based Medicine and The Marketing of Health Techology. Int J Rad Onc Biol Phys vol. 72 (1), 2008.